Skip to main content
DFTX logo

DFTX · Definium Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track DFTX — free
$29.12 -0.26 (-0.88%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$3.99B
Shares
136.90M
Volume · Nov 18 1.92M Avg daily vol (3M) 1.96M

Definium Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Definium Therapeutics, Inc. (DFTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-12-02
Definium Therapeutics, Inc. (DFTX) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-12-01
Definium Therapeutics, Inc. (DFTX) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-17
Definium Therapeutics, Inc. (DFTX) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-10
Definium Therapeutics, Inc. (DFTX) November 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-09
Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript
Confident tone PTSD expansion Regulatory progress and NDA filing DT402 autism pipeline
Diluted EPS
$-0.46
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-06
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Transcript
Confident tone DT120 ODT clinical efficacy in MDD (eMERGE) Commercial launch preparation for DT120 DT120 regulatory path and FDA alignment
Diluted EPS
$-1.44
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-06-22
Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
Confident tone DT120 Phase III Program (MDD/GAD) Pipeline Expansion (PTSD, ASD/DT402) Regulatory Progress & DEA Scheduling
Diluted EPS
$-0.71
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript
Confident tone Generalized Anxiety Disorder Program DT120 ODT Pipeline Progress Major Depressive Disorder Program
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Definium Therapeutics, Inc. (DFTX) Q3 2025 Earnings Call Transcript
Confident tone Phase III MM120 readouts in GAD and MDD ASCEND second Phase III in MDD MM402 / R-enantiomer of MDMA in autism
Diluted EPS
$-0.78
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Definium Therapeutics, Inc. (DFTX) Q2 2025 Earnings Call Transcript
Confident tone MM120 ODT Phase III trials Clinical readout timeline Phase IIb efficacy data
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Definium Therapeutics, Inc. (DFTX) Q1 2025 Earnings Call Transcript
Confident tone Disease Burden and Market Opportunity MM120 Phase 3 Program Execution New Chief Commercial Officer Onboarding
Diluted EPS
$-0.35
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Definium Therapeutics, Inc. (DFTX) Q4 2024 Earnings Call Transcript
Confident tone MM120 Phase 3 GAD Program (Voyage and Panorama) MDD Program (Emerge) Regulatory Designations and IP
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Definium Therapeutics, Inc. (DFTX) Q3 2024 Earnings Call Transcript
Confident tone MM120 ODT in GAD (Voyage and Panorama Phase 3 studies) MM120 ODT in MDD (Emerge Phase 3 study) Clinical execution and enrollment efficiency
Diluted EPS
$-0.27
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Definium Therapeutics, Inc. (DFTX) Q2 2024 Earnings Call Transcript
Confident tone MM120 Phase 3 in GAD Expansion into MDD FDA regulatory engagement
Diluted EPS
$-0.26
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Definium Therapeutics, Inc. (DFTX) Q1 2024 Earnings Call Transcript
Confident tone MM120 Phase IIb results in GAD Pipeline expansion and additional indications ODT formulation and IP
Diluted EPS
$-1.14
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Definium Therapeutics, Inc. (DFTX) Q4 2023 Earnings Call Transcript
Confident tone MM120 Phase 2b results in GAD Phase 3 development and End-of-Phase 2 meeting MM402 and R(-)-MDMA program in ASD
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Definium Therapeutics, Inc. (DFTX) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.45
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Definium Therapeutics, Inc. (DFTX) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.76
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Definium Therapeutics, Inc. (DFTX) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.65
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Definium Therapeutics, Inc. (DFTX) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Definium Therapeutics, Inc. (DFTX) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.56
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Definium Therapeutics, Inc. (DFTX) Q2 2022 Earnings Call
Diluted EPS
$-0.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Definium Therapeutics, Inc. (DFTX) Q1 2022 Earnings Call
Diluted EPS
$-0.66
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-28
Definium Therapeutics, Inc. (DFTX) Q4 2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 webcasts
Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 343 filings 335 filers Visit website Investor relations